Werewolf Therapeutics (HOWL) Competitors $1.34 -0.01 (-0.74%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$1.36 +0.02 (+1.87%) As of 01/31/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HOWL vs. AMLX, FHTX, NGNE, FULC, LRMR, LFCR, VIRI, MDWD, FDMT, and OCGNShould you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Amylyx Pharmaceuticals (AMLX), Foghorn Therapeutics (FHTX), Neurogene (NGNE), Fulcrum Therapeutics (FULC), Larimar Therapeutics (LRMR), Lifecore Biomedical (LFCR), Virios Therapeutics (VIRI), MediWound (MDWD), 4D Molecular Therapeutics (FDMT), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry. Werewolf Therapeutics vs. Amylyx Pharmaceuticals Foghorn Therapeutics Neurogene Fulcrum Therapeutics Larimar Therapeutics Lifecore Biomedical Virios Therapeutics MediWound 4D Molecular Therapeutics Ocugen Amylyx Pharmaceuticals (NASDAQ:AMLX) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking. Does the media favor AMLX or HOWL? In the previous week, Amylyx Pharmaceuticals had 5 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 8 mentions for Amylyx Pharmaceuticals and 3 mentions for Werewolf Therapeutics. Amylyx Pharmaceuticals' average media sentiment score of 0.65 beat Werewolf Therapeutics' score of 0.58 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Werewolf Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in AMLX or HOWL? 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer AMLX or HOWL? Amylyx Pharmaceuticals currently has a consensus price target of $7.33, indicating a potential upside of 100.91%. Werewolf Therapeutics has a consensus price target of $9.33, indicating a potential upside of 596.52%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.56Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AMLX or HOWL more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Amylyx Pharmaceuticals' return on equity of -36.97% beat Werewolf Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -36.97% -29.61% Werewolf Therapeutics -578.80%-58.83%-38.45% Which has more risk & volatility, AMLX or HOWL? Amylyx Pharmaceuticals has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Which has higher valuation & earnings, AMLX or HOWL? Amylyx Pharmaceuticals has higher revenue and earnings than Werewolf Therapeutics. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$196.49M1.27$49.27M-$3.82-0.96Werewolf Therapeutics$3.39M17.64-$37.37M-$1.53-0.88 Does the MarketBeat Community favor AMLX or HOWL? Amylyx Pharmaceuticals received 1 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. However, 69.57% of users gave Werewolf Therapeutics an outperform vote while only 66.00% of users gave Amylyx Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmylyx PharmaceuticalsOutperform Votes3366.00% Underperform Votes1734.00% Werewolf TherapeuticsOutperform Votes3269.57% Underperform Votes1430.43% SummaryAmylyx Pharmaceuticals beats Werewolf Therapeutics on 10 of the 18 factors compared between the two stocks. Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOWL vs. The Competition Export to ExcelMetricWerewolf TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.71M$6.86B$5.56B$9.11BDividend YieldN/A2.90%5.31%3.98%P/E Ratio-0.889.9789.9918.25Price / Sales17.64227.221,221.9274.93Price / CashN/A73.5045.9637.70Price / Book0.445.275.124.71Net Income-$37.37M$136.98M$111.09M$224.24M7 Day Performance-2.90%-0.62%2.38%1.08%1 Month Performance-9.46%0.15%3.20%1.51%1 Year Performance-71.85%7.68%24.70%20.44% Werewolf Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOWLWerewolf Therapeutics3.0543 of 5 stars$1.34-0.7%$9.33+596.5%-71.1%$59.72M$19.94M-0.8840Short Interest ↑AMLXAmylyx Pharmaceuticals3.0869 of 5 stars$3.49-3.1%$7.33+110.1%-77.2%$239.23M$196.49M-0.91200Short Interest ↑Analyst RevisionNews CoverageFHTXFoghorn Therapeutics2.5675 of 5 stars$4.12+1.5%$13.80+235.0%+31.8%$229.03M$34.15M-2.15120Analyst UpgradeShort Interest ↓Analyst RevisionNews CoverageNGNENeurogene3.2281 of 5 stars$15.08+0.1%$60.83+303.4%-47.4%$223.94MN/A0.0090News CoverageFULCFulcrum Therapeutics1.413 of 5 stars$4.10-1.4%$9.33+127.6%-45.2%$221.15M$2.81M-13.23100News CoveragePositive NewsLRMRLarimar Therapeutics1.7527 of 5 stars$3.46-3.4%$20.43+490.4%-33.7%$220.78MN/A-3.0130Analyst ForecastNews CoverageLFCRLifecore Biomedical2.7106 of 5 stars$5.95-5.9%$8.00+34.5%-9.0%$220.33M$128.26M-10.63690VIRIVirios Therapeutics0.3659 of 5 stars$11.40-14.6%$3.00-73.7%+3,012.2%$219.54MN/A-42.225High Trading VolumeMDWDMediWound1.9796 of 5 stars$20.23+2.0%$27.50+35.9%+53.3%$218.28M$18.69M-6.9880FDMT4D Molecular Therapeutics3.2557 of 5 stars$4.72+1.3%$38.56+716.9%-67.5%$218.21M$20.72M-1.66120Short Interest ↓OCGNOcugen1.5789 of 5 stars$0.73-6.3%$5.67+675.1%+35.7%$212.98M$6.04M-4.0680 Related Companies and Tools Related Companies Amylyx Pharmaceuticals Alternatives Foghorn Therapeutics Alternatives Neurogene Alternatives Fulcrum Therapeutics Alternatives Larimar Therapeutics Alternatives Lifecore Biomedical Alternatives Virios Therapeutics Alternatives MediWound Alternatives 4D Molecular Therapeutics Alternatives Ocugen Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HOWL) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
